Rectosigmoid carcinoma

disease
On this page

Also known as carcinoma of rectosigmoid junctionrectosigmoid cancerrectosigmoid junction carcinoma

Summary

Rectosigmoid carcinoma (MONDO:0002424) is a cancer and 10 clinical trials. Top therapeutic interventions include leucovorin. A subtype of colon carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namerectosigmoid carcinoma
Mondo IDMONDO:0002424
DOIDDOID:2781
ICD-111415734886
NCITC7421
UMLSC1327709
MedGen232963
Anatomy (UBERON)UBERON:0036214
Is cancer (heuristic)yes

Also known as: carcinoma of rectosigmoid junction · rectosigmoid cancer · rectosigmoid carcinoma · rectosigmoid junction carcinoma

Data availability: 8 cell lines.

Disease family

This is a subtype of colon carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderintestinal disorder › large intestine disorder › colonic disordercolonic neoplasmmalignant colon neoplasmcolon carcinomarectosigmoid carcinoma

Related subtypes (5): colon adenocarcinoma, colon small cell neuroendocrine carcinoma, colon carcinoma in situ, cecum carcinoma, squamous cell carcinoma of colon

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified8
PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03043729PHASE2COMPLETEDmFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
NCT04205955PHASE2COMPLETEDTesting Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
NCT02874885Not specifiedACTIVE_NOT_RECRUITINGCirculating Tumor Cells in Patients With Locally Advanced Rectal Cancer
NCT04037956Not specifiedRECRUITINGTubeless NOSES Versus Laparoscopic Radical Resection for Rectosigmoid Cancers
NCT04665635Not specifiedRECRUITINGRectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery
NCT05566249Not specifiedRECRUITINGA Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center Registry
NCT05797064Not specifiedNOT_YET_RECRUITINGEstablishment of a Feasibility Model for NOSE Surgery Based on Machine Learning
NCT02205307Not specifiedTERMINATEDA Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
NCT03063918Not specifiedCOMPLETEDPersonalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors
NCT06435975Not specifiedCOMPLETEDPhysical Activity in Rectal Cancer Survivors

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LEUCOVORIN41

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.